Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, United States; Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, United States.
Neuroscience. 2018 Jun 15;381:149-158. doi: 10.1016/j.neuroscience.2018.03.024.
Latent sensitization is a model of chronic pain in which an injury triggers a period of hyperalgesia followed by an apparent recovery, but in which pain sensitization persists but is suppressed by opioid and adrenergic receptors. One important characteristic of latent sensitization is that hyperalgesia can be triggered by acute stress. To determine whether the effect of stress is mimicked by the activation of corticotropin-releasing factor (CRF) signaling in the brain, rats with latent sensitization induced by injecting complete Freund's adjuvant (CFA, 50 μl) in one hind paw were given an intracerebroventricular (i.c.v.) injection of CRF. The i.c.v. injection of CRF (0.6 μg, 10 μl), but not saline, induced bilateral mechanical hyperalgesia in rats with latent sensitization. In contrast, CRF i.c.v. did not induce hyperalgesia in rats without latent sensitization (injected with saline in the hind paw). To determine whether descending pain inhibition mediates the suppression of hyperalgesia in latent sensitization, rats with CFA-induced latent sensitization received an intrathecal injection of lidocaine (10%, 1 μl) at the cervical-thoracic spinal cord to produce a spinal block. Lidocaine-injected rats, but not rats injected intrathecally with saline, developed bilateral mechanical hyperalgesia. Intrathecal lidocaine did not induce hyperalgesia in rats without latent sensitization (injected with saline in the hind paw). These results show that i.c.v. CRF mimicked the hyperalgesic response triggered by stress during latent sensitization, possibly by blocking inhibitory spinal descending signals that suppress hyperalgesia.
潜伏性痛敏是一种慢性疼痛模型,其中损伤引发一段时间的痛觉过敏,随后出现明显的恢复,但疼痛敏化持续存在,但被阿片类和肾上腺素能受体抑制。潜伏性痛敏的一个重要特征是,急性应激可以引发痛觉过敏。为了确定大脑中促肾上腺皮质释放因子(CRF)信号的激活是否模拟了应激的作用,将完全弗氏佐剂(CFA,50μl)注射到一只后爪中诱导出潜伏性痛敏的大鼠接受脑室内(i.c.v.)CRF 注射。CRF(0.6μg,10μl)的 i.c.v. 注射,但不是盐水,在有潜伏性痛敏的大鼠中引起双侧机械性痛觉过敏。相比之下,CRF i.c.v. 不会引起没有潜伏性痛敏的大鼠(后爪注射盐水)的痛觉过敏。为了确定下行性疼痛抑制是否介导潜伏性痛敏中痛觉过敏的抑制,用 CFA 诱导潜伏性痛敏的大鼠在颈胸脊髓接受利多卡因(10%,1μl)鞘内注射以产生脊髓阻滞。接受利多卡因注射的大鼠,但不是鞘内注射盐水的大鼠,出现双侧机械性痛觉过敏。鞘内注射利多卡因不会引起没有潜伏性痛敏的大鼠(后爪注射盐水)的痛觉过敏。这些结果表明,i.c.v. CRF 模拟了潜伏性痛敏期间应激引发的痛觉过敏反应,可能是通过阻断抑制性下行脊髓信号来抑制痛觉过敏。